• Explore /
  • Poster
  • / Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).

Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).

Abstract Poster

Authors

null

Matthias Philip Ebert

Department of Medicine II, University Hospital Mannheim, Heidelberg University, Mannheim, Germany

Matthias Philip Ebert , Nadja M Meindl-Beinker , Tobias Gutting , Martin Maenz , Johannes Betge , Nadine Schulte , Tianzuo Zhan , Philip Weidner , Ralf-Dieter Hofheinz , Arndt Vogel , Stefan Angermeier , Maike de Wit , Ralf Jakobs , Meinolf Karthaus , Gertraud Stocker , Peter C. Thuss-Patience , Tobias Leidig , Nicolai Haertel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03416244

DOI

10.1200/JCO.2022.40.4_suppl.303

Abstract #

303

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nadja M Meindl-Beinker

First Author: Nicolai Hartel

First Author: Ana-Alicia Beltran-Bless

First Author: Dirk Schadendorf